Printer Friendly

United States : ZOSANO PHARMA'S ZP-Glucagon Patch Phase 2 Study obtains Better outcomes.

Zosano Pharma Corporation, a clinical-stage specialty pharmaceutical firm, declared positive outcomes from the Phase 2 clinical trial of its proprietary, quick onset, transdermal ZP-Glucagon patch for severe hypoglycemia.

The goal of the Phase 2 clinical program was to assist the safety and efficacy of the ZP-Glucagon patch in comparison to the standard-of-care in reversing insulin ingested hypoglycemia in adult subjects with Type 1 diabetes.

2 doses of the ZP-Glucagon patch were in comparison with 2 doses of intramuscular injections in an open-label, randomized, 4-way crossover study design.

The 2 ZP-Glucagon patch doses eases blood sugar in 100% of the patients.

Both patch doses had quick onset of action and time to glucose response was alike among the 2 modes of administration.

Each cure were well tolerated and no new protection issues were recognized.

Thorsten von Stein, Chief Medical Officer said, "Achieving positive results from this Phase 2 study with the Zosano ZP-Glucagon patch is another significant milestone for the company. ZP-Glucagon s dry, stable formulation and simple press-and-apply application represents a significant improvement over the currently marketed products for treatment of severe hypoglycemia, which often require a lay person to deliver an injection with a cumbersome preparation and reconstitution process.

[c] 2015 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Article Type:Clinical report
Date:Oct 16, 2015
Previous Article:United States : NEW textile colour management tool launched by X-Rite.
Next Article:United States : AVIATION FIRM seeking to recruit 50 airplane mechanics locally.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters